title: Gut microbiota in chronic kidney disease.
abstract: The intestinal microflora maintains a symbiotic relationship with the host under normal conditions, but its imbalance has recently been associated with several diseases. In chronic kidney disease (CKD), dysbiotic intestinal microflora has been reported with an increase in pathogenic flora compared to symbiotic flora. An enhanced permeability of the intestinal barrier, allowing the passage of endotoxins and other bacterial products to the blood, has also been shown in CKD. By fermenting undigested products that reach the colon, the intestinal microflora produce indoles, phenols and amines, among others, that are absorbed by the host, accumulate in CKD and have harmful effects on the body. These gut-derived uraemic toxins and the increased permeability of the intestinal barrier in CKD have been associated with increased inflammation and oxidative stress and have been involved in various CKD-related complications, including cardiovascular disease, anaemia, mineral metabolism disorders or the progression of CKD. The use of prebiotics, probiotics or synbiotics, among other approaches, could improve the dysbiosis and/or the increased permeability of the intestinal barrier in CKD. This article describes the situation of the intestinal microflora in CKD, the alteration of the intestinal barrier and its clinical consequences, the harmful effects of intestinal flora-derived uraemic toxins, and possible therapeutic options to improve this dysbiosis and reduce CKD-related complications.
authors.affiliation: Sección de Nefrología, Hospital Da Costa, Burela (Lugo), España. Electronic address: secundino.cigarran.guldris@sergas.es.
authors.forename: Secundino
authors.initials: S
authors.lastname: Cigarran Guldris
authors.affiliation: Servicio de Nefrología, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, España.
authors.forename: Emilio
authors.initials: E
authors.lastname: González Parra
authors.affiliation: Servicio de Nefrología, Hospital Clinic, Universitat de Barcelona, Barcelona, España.
authors.forename: Aleix
authors.initials: A
authors.lastname: Cases Amenós
mesh_terms: D064806:Dysbiosis / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D004731:Endotoxins / Q000009:adverse effects / Q000493:pharmacokinetics; D000069196:Gastrointestinal Microbiome / Q000502:physiology*; D006801:Humans; D007249:Inflammation; D007408:Intestinal Absorption; D018384:Oxidative Stress; D056692:Prebiotics; D019936:Probiotics / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000382:microbiology*; D014511:Uremia / Q000378:metabolism / Q000382:microbiology
chemical_list: D004731:Endotoxins; D056692:Prebiotics
keywords: Chronic kidney disease; Disbiosis; Dysbiosis; Enfermedad renal crónica; Gut microbiota; Inflamación; Inflammation; Microbiota intestinal; Toxinas urémicas; Uraemic toxins